Alpha Teknova, Inc. (NASDAQ:TKNO – Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,660,000 shares, a growth of 72.2% from the February 13th total of 964,000 shares. Approximately 15.7% of the shares of the stock are sold short. Based on an average daily volume of 319,200 shares, the days-to-cover ratio is presently 5.2 days.
Analysts Set New Price Targets
Separately, Craig Hallum initiated coverage on shares of Alpha Teknova in a research report on Monday, February 10th. They set a “buy” rating and a $12.00 price objective for the company.
View Our Latest Report on Alpha Teknova
Alpha Teknova Trading Up 7.3 %
Alpha Teknova (NASDAQ:TKNO – Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.11) EPS for the quarter. The company had revenue of $9.27 million during the quarter, compared to the consensus estimate of $9.10 million. Alpha Teknova had a negative return on equity of 35.30% and a negative net margin of 87.17%. Analysts predict that Alpha Teknova will post -0.58 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in TKNO. Invesco Ltd. bought a new position in shares of Alpha Teknova in the fourth quarter worth about $9,236,000. Point72 Asset Management L.P. bought a new position in shares of Alpha Teknova in the third quarter worth about $1,483,000. Susquehanna International Group LLP lifted its holdings in shares of Alpha Teknova by 472.5% in the fourth quarter. Susquehanna International Group LLP now owns 209,409 shares of the company’s stock worth $1,749,000 after acquiring an additional 172,828 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of Alpha Teknova in the fourth quarter worth about $744,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Alpha Teknova in the fourth quarter valued at approximately $716,000. Institutional investors own 13.81% of the company’s stock.
About Alpha Teknova
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Featured Stories
- Five stocks we like better than Alpha Teknova
- Using the MarketBeat Stock Split Calculator
- How to Build the Ultimate Everything ETF Portfolio
- What Are Dividend Champions? How to Invest in the Champions
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Insider Buying Explained: What Investors Need to Know
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.